Furthermore, activation of AR with supraphysiologic testosterone47,48 or cycles of androgen stimulation/deprivation (bipolar androgen therapy) in PCa patients49–52 has emerged as promising therapeutic strategies, with clinical trials in progress. The gene discussed is AR; the disease is posterior cortical atrophy.